Mrna疫苗无菌过滤后的定量和定性评价

R. Trittler, B. Altmann, M. Garcia-Käufer, R. Gminski, M. Hug
{"title":"Mrna疫苗无菌过滤后的定量和定性评价","authors":"R. Trittler, B. Altmann, M. Garcia-Käufer, R. Gminski, M. Hug","doi":"10.1136/ejhpharm-2022-eahp.49","DOIUrl":null,"url":null,"abstract":"Background and importance The importance of mRNA-based vaccines increased rapidly due to the COVID-19 pandemic. However, little is known on the challenges linked to handling shortages and extended stability of these new types of substance. Since vaccine remnants have to be discarded according to the Summary of Product Characteristics, we hypothesise that sterile filtration after pooling is suitable to save vaccine material for clinical application. Aim and objectives The aim of this pilot study was to compare quality parameters of remnants derived from ready-to-use mRNA vaccine solutions before and after sterile filtration. Therefore, we pooled mRNA vaccine solution remnants from Corminaty vials (BioNTech/Pfizer) and compared particle size, distribution and quantity of the lipoplexes. In addition, quantity and/or quality of the mRNA was determined. Material and methods Measurements of invisible particulates in the range 1-50 mm were performed by light obscuration according to the European Pharmacopoeia (10th edn). The size of lipoplexes was measured with nanoparticle tracking analysis (NTA) to determine hydrodynamic diameter and particle concentration. Dynamic light scattering was employed complementarily to the NTA technique to focus on particle size from 0.3 nm to 10 mm. The concentration, purity and integrity of the mRNA was analysed by ultraviolet (UV) spectrophotometry and capillary electrophoresis after mRNA purification. Results After pooling the remnants of the vials we found a substantial increase of particulates >1 mm when compared to fresh vaccine samples. This effect was likely due to contamination of the examined probes with particles from ambient air. As expected, all these particulates were eliminated by sterile filtration. Size distribution and concentration of the lipoplexes were comparable between unfiltered and filtered samples. With respect to the mRNA, we identified the fragment of interest in all examined samples. Sterile filtration did not change the concentration, purity and integrity of the mRNA. Conclusion and relevance Our results indicate that sterile filtration of mRNA-based vaccines eliminates particle contamination from the vaccine solution while the concentration of lipoplex nanoparticles was not altered. Moreover, neither the quantity nor quality of the mRNA was affected by the filtration process. The results of our pilot study provide the first data on the stability of mRNA vaccines and help to fill knowledge gap when dealing with these substances in hospital pharmacy.","PeriodicalId":11998,"journal":{"name":"European Journal of Hospital Pharmacy","volume":"53 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Quantitative and Qualitative Evaluation of Mrna Vaccines after Sterile Filtration\",\"authors\":\"R. Trittler, B. Altmann, M. Garcia-Käufer, R. Gminski, M. Hug\",\"doi\":\"10.1136/ejhpharm-2022-eahp.49\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and importance The importance of mRNA-based vaccines increased rapidly due to the COVID-19 pandemic. However, little is known on the challenges linked to handling shortages and extended stability of these new types of substance. Since vaccine remnants have to be discarded according to the Summary of Product Characteristics, we hypothesise that sterile filtration after pooling is suitable to save vaccine material for clinical application. Aim and objectives The aim of this pilot study was to compare quality parameters of remnants derived from ready-to-use mRNA vaccine solutions before and after sterile filtration. Therefore, we pooled mRNA vaccine solution remnants from Corminaty vials (BioNTech/Pfizer) and compared particle size, distribution and quantity of the lipoplexes. In addition, quantity and/or quality of the mRNA was determined. Material and methods Measurements of invisible particulates in the range 1-50 mm were performed by light obscuration according to the European Pharmacopoeia (10th edn). The size of lipoplexes was measured with nanoparticle tracking analysis (NTA) to determine hydrodynamic diameter and particle concentration. Dynamic light scattering was employed complementarily to the NTA technique to focus on particle size from 0.3 nm to 10 mm. The concentration, purity and integrity of the mRNA was analysed by ultraviolet (UV) spectrophotometry and capillary electrophoresis after mRNA purification. Results After pooling the remnants of the vials we found a substantial increase of particulates >1 mm when compared to fresh vaccine samples. This effect was likely due to contamination of the examined probes with particles from ambient air. As expected, all these particulates were eliminated by sterile filtration. Size distribution and concentration of the lipoplexes were comparable between unfiltered and filtered samples. With respect to the mRNA, we identified the fragment of interest in all examined samples. Sterile filtration did not change the concentration, purity and integrity of the mRNA. Conclusion and relevance Our results indicate that sterile filtration of mRNA-based vaccines eliminates particle contamination from the vaccine solution while the concentration of lipoplex nanoparticles was not altered. Moreover, neither the quantity nor quality of the mRNA was affected by the filtration process. The results of our pilot study provide the first data on the stability of mRNA vaccines and help to fill knowledge gap when dealing with these substances in hospital pharmacy.\",\"PeriodicalId\":11998,\"journal\":{\"name\":\"European Journal of Hospital Pharmacy\",\"volume\":\"53 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Hospital Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2022-eahp.49\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2022-eahp.49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

由于COVID-19大流行,基于mrna的疫苗的重要性迅速增加。然而,人们对处理这些新型物质的短缺和延长稳定性所面临的挑战知之甚少。由于根据产品特性总结,疫苗残余物必须被丢弃,我们假设池化后的无菌过滤适合于节省疫苗材料用于临床应用。目的和目的本初步研究的目的是比较无菌过滤前后即用mRNA疫苗溶液残留物的质量参数。因此,我们收集了来自Corminaty小瓶(BioNTech/Pfizer)的mRNA疫苗溶液残余物,并比较了脂质体的粒径、分布和数量。此外,测定mRNA的数量和/或质量。材料和方法根据欧洲药典(第10版)采用遮光法测量1- 50mm范围内的不可见颗粒。采用纳米颗粒跟踪分析(NTA)测量脂丛的大小,以确定流体动力学直径和颗粒浓度。动态光散射与NTA技术互补,聚焦于0.3 nm至10 mm的颗粒尺寸。mRNA纯化后,用紫外分光光度法和毛细管电泳法分析mRNA的浓度、纯度和完整性。结果在收集残余物后,我们发现与新鲜疫苗样品相比,>1 mm的颗粒显著增加。这种影响很可能是由于被检查的探针受到周围空气颗粒的污染。正如预期的那样,所有这些微粒都通过无菌过滤消除了。在未过滤和过滤的样品中,脂质体的大小分布和浓度具有可比性。关于mRNA,我们在所有检测样本中确定了感兴趣的片段。无菌过滤未改变mRNA的浓度、纯度和完整性。结论与相关性我们的研究结果表明,mrna疫苗的无菌过滤消除了疫苗溶液中的颗粒污染,而脂质体纳米颗粒的浓度没有改变。此外,mRNA的数量和质量都不受过滤过程的影响。我们的初步研究结果提供了mRNA疫苗稳定性的第一个数据,并有助于填补医院药房在处理这些物质时的知识空白。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Quantitative and Qualitative Evaluation of Mrna Vaccines after Sterile Filtration
Background and importance The importance of mRNA-based vaccines increased rapidly due to the COVID-19 pandemic. However, little is known on the challenges linked to handling shortages and extended stability of these new types of substance. Since vaccine remnants have to be discarded according to the Summary of Product Characteristics, we hypothesise that sterile filtration after pooling is suitable to save vaccine material for clinical application. Aim and objectives The aim of this pilot study was to compare quality parameters of remnants derived from ready-to-use mRNA vaccine solutions before and after sterile filtration. Therefore, we pooled mRNA vaccine solution remnants from Corminaty vials (BioNTech/Pfizer) and compared particle size, distribution and quantity of the lipoplexes. In addition, quantity and/or quality of the mRNA was determined. Material and methods Measurements of invisible particulates in the range 1-50 mm were performed by light obscuration according to the European Pharmacopoeia (10th edn). The size of lipoplexes was measured with nanoparticle tracking analysis (NTA) to determine hydrodynamic diameter and particle concentration. Dynamic light scattering was employed complementarily to the NTA technique to focus on particle size from 0.3 nm to 10 mm. The concentration, purity and integrity of the mRNA was analysed by ultraviolet (UV) spectrophotometry and capillary electrophoresis after mRNA purification. Results After pooling the remnants of the vials we found a substantial increase of particulates >1 mm when compared to fresh vaccine samples. This effect was likely due to contamination of the examined probes with particles from ambient air. As expected, all these particulates were eliminated by sterile filtration. Size distribution and concentration of the lipoplexes were comparable between unfiltered and filtered samples. With respect to the mRNA, we identified the fragment of interest in all examined samples. Sterile filtration did not change the concentration, purity and integrity of the mRNA. Conclusion and relevance Our results indicate that sterile filtration of mRNA-based vaccines eliminates particle contamination from the vaccine solution while the concentration of lipoplex nanoparticles was not altered. Moreover, neither the quantity nor quality of the mRNA was affected by the filtration process. The results of our pilot study provide the first data on the stability of mRNA vaccines and help to fill knowledge gap when dealing with these substances in hospital pharmacy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信